Schütz, Ekkehard

[["dc.bibliographiccitation.firstpage","153"],["dc.bibliographiccitation.lastpage","176"],["dc.contributor.author","Oellerich, Michael"],["dc.contributor.author","Beck, Julia"],["dc.contributor.author","Kanzow, Philipp"],["dc.contributor.author","Schmitz, Jessica"],["dc.contributor.author","Kollmar, Otto"],["dc.contributor.author","Walson, Philip D."],["dc.contributor.author","Schütz, Ekkehard"],["dc.contributor.editor","Oellerich, Michael"],["dc.contributor.editor","Dasgupta, Amitava"],["dc.date.accessioned","2020-05-22T06:58:17Z"],["dc.date.available","2020-05-22T06:58:17Z"],["dc.date.issued","2016"],["dc.description.abstract","Genome transplant dynamics is a particularly promising new approach for the detection of graft injury based on the determination of graft-derived circulating cell-free DNA (cfDNA) in the blood of the recipient. An increase of donor DNA is an early indication of organ damage. A novel potential routine assay for graft-derived circulating cfDNA quantification has been developed using droplet digital polymerase chain reaction for the determination of the donor/recipient circulating cfDNA ratio. This method is very cost-effective and provides results on the same day. Monitoring graft-derived cfDNA has the advantage that it directly interrogates the health of the donor organ, and it allows early detection of transplant injury (“liquid biopsy”). The detection of subclinical rejection would be desirable to allow early intervention. Undiagnosed chronic damage can result in chronic rejection. The determination of graft-derived circulating cfDNA may complement or possibly replace other approaches for post-transplant monitoring, and it may improve the chances of long-term graft survival. This method will be helpful to individualize immunosuppressive regimens. Personalized immunosuppression will in the future shift emphasis from reaction to prevention, which could make immunosuppressive drugs safer and more effective and also reduce the cost of health care."],["dc.identifier.doi","10.1016/B978-0-12-800885-0.00007-2"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/65676"],["dc.language.iso","en"],["dc.publisher","Elsevier"],["dc.publisher.place","San Diego"],["dc.relation.doi","10.1016/C2013-0-19247-1"],["dc.relation.isbn","978-0-12-800885-0"],["dc.relation.ispartof","Personalized Immunosuppression in Transplantation"],["dc.title","Graft-derived cell-free DNA as a marker of graft integrity after transplantation"],["dc.type","book_chapter"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","American Journal of Transplantation"],["dc.bibliographiccitation.volume","14"],["dc.contributor.author","Oellerich, M."],["dc.contributor.author","Kanzow, Philipp"],["dc.contributor.author","Beck, J."],["dc.contributor.author","Schmitz, J."],["dc.contributor.author","Kollmar, Otto"],["dc.contributor.author","Walson, Philip D."],["dc.contributor.author","Schütz, Ekkehard"],["dc.date.accessioned","2018-11-07T09:39:13Z"],["dc.date.available","2018-11-07T09:39:13Z"],["dc.date.issued","2014"],["dc.format.extent","874"],["dc.identifier.isi","000338033304007"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/33231"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.publisher.place","Hoboken"],["dc.relation.conference","World Transplant Congress"],["dc.relation.eventlocation","San Francisco, CA"],["dc.relation.issn","1600-6143"],["dc.relation.issn","1600-6135"],["dc.title","Graft-Derived Cell-Free DNA (GcfDNA) as a Sensitive Measure of Individual Graft Integrity After Liver Transplantation."],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","373"],["dc.bibliographiccitation.lastpage","386"],["dc.contributor.author","Oellerich, Michael"],["dc.contributor.author","Schütz, Ekkehard"],["dc.contributor.author","Beck, Julia"],["dc.contributor.author","Kollmar, Otto"],["dc.contributor.author","Kanzow, Philipp"],["dc.contributor.author","Blum, Anna"],["dc.contributor.author","Walson, Philip D."],["dc.contributor.editor","Preedy, V. R."],["dc.contributor.editor","Patel, V. B."],["dc.date.accessioned","2020-05-22T07:14:29Z"],["dc.date.available","2020-05-22T07:14:29Z"],["dc.date.issued","2017"],["dc.description.abstract","Improvement of long-term patient and graft outcome is still a challenge in liver transplantation. Personalized approaches to immunosuppressive treatment of liver transplant patients are currently under investigation, as conventional markers have limited usefulness to predict drug efficacy. The presence of graft-derived cell-free DNA (GcfDNA) in the plasma of liver transplant recipients opens up the possibility of monitoring allograft injury through measurement of this molecular marker. A rapid, cost-effective droplet digital PCR (ddPCR) method has been developed for the quantification of donor DNA. GcfDNA has shown to be useful for the detection of subclinical and full-blown acute rejection and non-rejection-related liver injury (e.g., HCV infection, liver trauma, ischemia/reperfusion damage). GcfDNA allows for the early detection of transplant injury (“liquid biopsy”) and enables earlier more effective treatment intervention. It is especially helpful to guide changes in immunosuppression and to monitor immunosuppression minimization. This new approach may contribute to achieve more effective, less toxic personalized immunosuppression."],["dc.identifier.doi","10.1007/978-94-007-7675-3_10"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/65684"],["dc.language.iso","en"],["dc.publisher","Springer"],["dc.publisher.place","Dordrecht"],["dc.relation.eisbn","978-94-007-7675-3"],["dc.relation.isbn","978-94-007-7674-6"],["dc.relation.ispartof","Biomarkers in Liver Disease"],["dc.title","Graft-derived cell-free DNA as a biomarker in liver transplantation"],["dc.type","book_chapter"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","713"],["dc.bibliographiccitation.journal","American Journal of Transplantation"],["dc.bibliographiccitation.lastpage","714"],["dc.bibliographiccitation.volume","14"],["dc.contributor.author","Kanzow, Philipp"],["dc.contributor.author","Kollmar, Otto"],["dc.contributor.author","Oellerich, M."],["dc.contributor.author","Schütz, Ekkehard"],["dc.contributor.author","Schmitz, J."],["dc.contributor.author","Beck, J."],["dc.contributor.author","Slotta, Jan Erik"],["dc.contributor.author","Walson, Philip D."],["dc.date.accessioned","2018-11-07T09:39:13Z"],["dc.date.available","2018-11-07T09:39:13Z"],["dc.date.issued","2014"],["dc.identifier.isi","000338033303192"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/33230"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.publisher.place","Hoboken"],["dc.relation.conference","World Transplant Congress"],["dc.relation.eventlocation","San Francisco, CA"],["dc.relation.issn","1600-6143"],["dc.relation.issn","1600-6135"],["dc.title","Potential of Graft-Derived Cell-Free DNA Quantification to Improve Outcomes With Marginal Donor Organs - Case Report of Successful Liver Transplantation of a HELLP Syndrome Donor."],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Transplantation Journal"],["dc.bibliographiccitation.volume","98"],["dc.contributor.author","Oellerich, M."],["dc.contributor.author","Kanzow, Philipp"],["dc.contributor.author","Beck, J."],["dc.contributor.author","Schmitz, J."],["dc.contributor.author","Kollmar, Otto"],["dc.contributor.author","Walson, Philip D."],["dc.contributor.author","Schütz, Ekkehard"],["dc.date.accessioned","2018-11-07T09:37:41Z"],["dc.date.available","2018-11-07T09:37:41Z"],["dc.date.issued","2014"],["dc.format.extent","874"],["dc.identifier.isi","000339104605413"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/32898"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.publisher.place","Philadelphia"],["dc.relation.conference","World Transplant Congress"],["dc.relation.eventlocation","San Francisco, CA"],["dc.relation.issn","1534-6080"],["dc.relation.issn","0041-1337"],["dc.title","Graft-Derived Cell-Free DNA (GcfDNA) as a Sensitive Measure of Individual Graft Integrity After Liver Transplantation."],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","S241"],["dc.bibliographiccitation.journal","Liver Transplantation"],["dc.bibliographiccitation.lastpage","S242"],["dc.bibliographiccitation.volume","20"],["dc.contributor.author","Slotta, Jan Erik"],["dc.contributor.author","Kanzow, Philipp"],["dc.contributor.author","Schuetz, Ekkehardt"],["dc.contributor.author","Oellerich, Michael"],["dc.contributor.author","Kollmar, Otto"],["dc.date.accessioned","2018-11-07T09:39:07Z"],["dc.date.available","2018-11-07T09:39:07Z"],["dc.date.issued","2014"],["dc.identifier.isi","000339959602142"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/33206"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.publisher.place","Hoboken"],["dc.relation.conference","Joint International Congress of ILTS, ELITA and LICAGE"],["dc.relation.eventlocation","London, ENGLAND"],["dc.relation.issn","1527-6473"],["dc.relation.issn","1527-6465"],["dc.title","Graft Derived Cell-Free DNA as an Early Organ Integrity Biomarker after Liver Transplantation of a HELLP Syndrome Donor Liver."],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","205"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Critical Reviews in Clinical Laboratory Sciences"],["dc.bibliographiccitation.lastpage","218"],["dc.bibliographiccitation.volume","54"],["dc.contributor.author","Oellerich, Michael"],["dc.contributor.author","Schütz, Ekkehard"],["dc.contributor.author","Beck, Julia"],["dc.contributor.author","Kanzow, Philipp"],["dc.contributor.author","Plowman, Piers N."],["dc.contributor.author","Weiss, Glen J."],["dc.contributor.author","Walson, Philip D."],["dc.date.accessioned","2018-11-07T10:24:20Z"],["dc.date.accessioned","2020-05-22T07:29:56Z"],["dc.date.available","2018-11-07T10:24:20Z"],["dc.date.available","2020-05-22T07:29:56Z"],["dc.date.issued","2017"],["dc.description.abstract","High-quality genomic analysis is critical for personalized pharmacotherapy in patients with cancer. Tumor-specific genomic alterations can be identified in cell-free DNA (cfDNA) from patient blood samples and can complement biopsies for real-time molecular monitoring of treatment, detection of recurrence, and tracking resistance. cfDNA can be especially useful when tumor tissue is unavailable or insufficient for testing. For blood-based genomic profiling, next-generation sequencing (NGS) and droplet digital PCR (ddPCR) have been successfully applied. The US Food and Drug Administration (FDA) recently approved the first such \"liquid biopsy\" test for EGFR mutations in patients with non-small cell lung cancer (NSCLC). Such non-invasive methods allow for the identification of specific resistance mutations selected by treatment, such as EGFR T790M, in patients with NSCLC treated with gefitinib. Chromosomal aberration pattern analysis by low coverage whole genome sequencing is a more universal approach based on genomic instability. Gains and losses of chromosomal regions have been detected in plasma tumor-specific cfDNA as copy number aberrations and can be used to compute a genomic copy number instability (CNI) score of cfDNA. A specific CNI index obtained by massive parallel sequencing discriminated those patients with prostate cancer from both healthy controls and men with benign prostatic disease. Furthermore, androgen receptor gene aberrations in cfDNA were associated with therapeutic resistance in metastatic castration resistant prostate cancer. Change in CNI score has been shown to serve as an early predictor of response to standard chemotherapy for various other cancer types (e.g. NSCLC, colorectal cancer, pancreatic ductal adenocarcinomas). CNI scores have also been shown to predict therapeutic responses to immunotherapy. Serial genomic profiling can detect resistance mutations up to 16 weeks before radiographic progression. There is a potential for cost savings when ineffective use of expensive new anticancer drugs is avoided or halted. Challenges for routine implementation of liquid biopsy tests include the necessity of specialized personnel, instrumentation, and software, as well as further development of quality management (e.g. external quality control). Validation of blood-based tumor genomic profiling in additional multicenter outcome studies is necessary; however, cfDNA monitoring can provide clinically important actionable information for precision oncology approaches."],["dc.description.sponsorship","Chronix Biomedical"],["dc.identifier.doi","10.1080/10408363.2017.1299683"],["dc.identifier.isi","000401250100004"],["dc.identifier.pmid","28393575"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/65692"],["dc.language.iso","en"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.relation.eissn","1549-781X"],["dc.relation.issn","1040-8363"],["dc.title","Using circulating cell-free DNA to monitor personalized cancer therapy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1732"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","Clinical Chemistry"],["dc.bibliographiccitation.lastpage","1741"],["dc.bibliographiccitation.volume","59"],["dc.contributor.author","Beck, Julia"],["dc.contributor.author","Bierau, Sarah"],["dc.contributor.author","Balzer, Stefan"],["dc.contributor.author","Andag, Reiner"],["dc.contributor.author","Kanzow, Philipp"],["dc.contributor.author","Schmitz, Jessica"],["dc.contributor.author","Gaedcke, Jochen"],["dc.contributor.author","Mörer, Onnen"],["dc.contributor.author","Slotta, Jan E."],["dc.contributor.author","Walson, Philip D."],["dc.contributor.author","Kollmar, Otto"],["dc.contributor.author","Oellerich, Michael"],["dc.contributor.author","Schütz, Ekkehard"],["dc.date.accessioned","2020-05-22T07:07:40Z"],["dc.date.available","2020-05-22T07:07:40Z"],["dc.date.issued","2013"],["dc.description.abstract","BACKGROUND Cell-free DNA (cfDNA) from grafts in the circulation of transplant recipients is a potential biomarker of rejection. Its usefulness was investigated after heart transplantation during the maintenance phase by use of microarrays and massive parallel sequencing of donor and recipient DNA. Disadvantages of these methods are high costs, long turnaround times, and need for donor DNA. Therefore, we sought to develop a rapid and cost-effective method using digital droplet PCR (ddPCR). METHODS Plasma samples were collected from stable recipients after liver (LTx, n = 10), kidney (KTx, n = 9), and heart (HTx, n = 8) transplantation as well as from 7 additional patients directly after LTx. Known single-nucleotide polymorphisms were selected for high minor allelic frequencies, of which 41 hydrolysis probe assays were established. Plasma cfDNA was preamplified, followed by conventional real-time PCR to define informative (heterologous) SNPs, which were then used for quantification (percentage) of graft-derived cfDNA (GcfDNA) using ddPCR. RESULTS Mean recovery was 94% (SD, 13%) with an imprecision of 4%–14% with the use of controls with 2% minor allele. GcfDNA in stable patients was <6.8% (LTx), <2.5% (KTx), and <3.4% (HTx). On the day of LTx, GcfDNA was approximately 90% and by day 10 it was <15% in complication-free LTx recipients. In 2 patients with biopsy-proven rejection, GcfDNA increased to >60%, whereas in 1 patient with cholestasis no increase was found. CONCLUSIONS A novel, cost-effective, rapid technique was developed to quantify GcfDNA in transplant recipients. This technique embodies a promising, potentially universal biomarker for early detection of rejection, which could enable more effective therapeutic interventions."],["dc.identifier.doi","10.1373/clinchem.2013.210328"],["dc.identifier.pmid","24061615"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/65680"],["dc.language.iso","en"],["dc.relation.eissn","1530-8561"],["dc.relation.issn","0009-9147"],["dc.title","Digital droplet PCR for rapid quantification of donor DNA in the circulation of transplant recipients as a potential universal biomarker of graft injury"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Transplant International"],["dc.bibliographiccitation.volume","27"],["dc.contributor.author","Beck, J."],["dc.contributor.author","Schmitz, J."],["dc.contributor.author","Kollmar, Otto"],["dc.contributor.author","Slotta, Jan Erik"],["dc.contributor.author","Kanzow, Philipp"],["dc.contributor.author","Walson, Philip D."],["dc.contributor.author","Oellerich, M."],["dc.contributor.author","Schütz, Ekkehard"],["dc.date.accessioned","2018-11-07T09:34:43Z"],["dc.date.available","2018-11-07T09:34:43Z"],["dc.date.issued","2014"],["dc.format.extent","50"],["dc.identifier.isi","000342752400154"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/32234"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.publisher.place","Hoboken"],["dc.relation.issn","1432-2277"],["dc.relation.issn","0934-0874"],["dc.title","USE OF PLASMA GCFDNA QUANTIFICATION TO GUIDE PERSONALIZED IMMUNOSUPPRESSION"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","S107"],["dc.bibliographiccitation.journal","Liver Transplantation"],["dc.bibliographiccitation.lastpage","S108"],["dc.bibliographiccitation.volume","20"],["dc.contributor.author","Slotta, Jan Erik"],["dc.contributor.author","Beck, Julia"],["dc.contributor.author","Birau, Sarah"],["dc.contributor.author","Balzer, Stefan"],["dc.contributor.author","Andag, Reiner"],["dc.contributor.author","Kanzow, Philipp"],["dc.contributor.author","Schmitz, Jessica"],["dc.contributor.author","Gaedcke, Jochen"],["dc.contributor.author","Moerer, Onnen"],["dc.contributor.author","Walson, Philip D."],["dc.contributor.author","Oellerich, Michael"],["dc.contributor.author","Schuetz, Eckehardt"],["dc.contributor.author","Kollmar, Otto"],["dc.date.accessioned","2018-11-07T09:39:07Z"],["dc.date.available","2018-11-07T09:39:07Z"],["dc.date.issued","2014"],["dc.identifier.isi","000339959601015"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/33207"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.publisher.place","Hoboken"],["dc.relation.conference","Joint International Congress of ILTS, ELITA and LICAGE"],["dc.relation.eventlocation","London, ENGLAND"],["dc.relation.issn","1527-6473"],["dc.relation.issn","1527-6465"],["dc.title","Quantification of Donor DNA in the Circulation after Liver Transplantation As a Potential Universal Rejection Biomarker Using Digital Droplet PCR."],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]